Meta-analysis of randomized controlled trials on effect of angiotensin-converting enzyme inhibitors on cancer risk

American Journal of Cardiology

Volumn 108, Issue 2, 2011, Pages 294-301

  Sipahi, Ilke ^a   Chou, Josephine ^a   Mishra, Prasun ^a   Debanne, Sara M ^b   Simon, Daniel I ^a   Fang, James C ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; AMLODIPINE; ATENOLOL; CAPTOPRIL; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FELODIPINE; FOSINOPRIL; HYDRALAZINE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISRADIPINE; LISINOPRIL; METOPROLOL; PINDOLOL; PLACEBO; PRAVASTATIN; QUINAPRIL; RAMIPRIL; RESERPINE;

ARTICLE; CANCER MORTALITY; CANCER RISK; CARDIOVASCULAR DISEASE; CAROTID ATHEROSCLEROSIS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIGESTIVE SYSTEM CANCER; DRUG EFFECT; DRUG FATALITY; HEART INFARCTION; HUMAN; HYPERTENSION; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCLERODERMA; SIDE EFFECT; SYSTOLIC HEART FAILURE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZAZEPINES; CAPTOPRIL; ENALAPRIL; FOSINOPRIL; HUMANS; LISINOPRIL; NEOPLASMS; RAMIPRIL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TETRAHYDROISOQUINOLINES;

EID: 79959748027     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2011.03.038     Document Type: Article

References (33)

1. A.J. George, W.G. Thomas, and R.D. Hannan The renin-angiotensin system and cancer: old dog, new tricks Nat Rev Cancer 10 2010 745 759
2. E.I. Ager, J. Neo, and C. Christophi The renin-angiotensin system and malignancy Carcinogenesis 29 2008 1675 1684
3. I. Sipahi, S.M. Debanne, D.Y. Rowland, D.I. Simon, and J.C. Fang Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials Lancet Oncol 11 2010 627 636
4. H. Krumholz Angiotensin-receptor blockers and cancer: an inconvenient truth? Journal Watch Cardiology, 2010 http://cardiology.jwatch.org/cgi/content/ full/2010/613/1 Accessed on April 22, 2011
5. M. Bohm, U. Laufs, and M. Pfreundschuh Angiotensin-receptor blockade, cancer, and concerns Lancet Oncol 11 2010 818 819
6. The SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure N Engl J Med 325 1991 293 302
7. The SOLVD Investigators Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions N Engl J Med 327 1992 685 691
8. K.M. Dale, C.I. Coleman, N.N. Henyan, J. Kluger, and C.M. White Statins and cancer risk: a meta-analysis JAMA 295 2006 74 80 (Pubitemid 43042692)
9. G. Maschio, D. Alberti, G. Janin, F. Locatelli, J.F. Mann, M. Motolese, C. Ponticelli, E. Ritz, P. Zucchelli The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency N Engl J Med 334 1996 939 945 (Pubitemid 26114159)
10. S. Lders, J. Schrader, J. Berger, T. Unger, W. Zidek, M. Bhm, M. Middeke, W. Motz, C. Lbcke, A. Gansz, L. Brokamp, R.E. Schmieder, P. Trenkwalder, H. Haller, and P. Dominiak The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League J Hypertens 26 2008 1487 1496
11. K.K. Teo, J.R. Burton, C.E. Buller, S. Plante, D. Catellier, W. Tymchak, V. Dzavik, D. Taylor, S. Yokoyama, and T.J. Montague Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT) Circulation 102 2000 1748 1754
12. F.X. Kleber, L. Niemller, and W. Doering Impact of converting enzyme inhibition on progression of chronic heart failure: results of the Munich Mild Heart Failure Trial Br Heart J 67 1992 289 296
13. M.A. Pfeffer, E. Braunwald, L.A. Moyé, L. Basta, E.J. Brown Jr, T.E. Cuddy, B.R. Davis, E.M. Geltman, S. Goldman, G.C. Flaker, M. Klein, G.A. Lamas, M. Packer, J. Rouleau, J.L. Rouleau, J. Rutherford, J.H. Wertheimer, C.M. Hawkins The SAVE Investigators Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction Results of the Survival And Ventricular Enlargement trial N Engl J Med 327 1992 669 677
14. A.E. Gliddon, C.J. Doré, C.M. Black, N. McHugh, R. Moots, C.P. Denton, A. Herrick, T. Barnes, J. Camilleri, K. Chakravarty, P. Emery, B. Griffiths, N.D. Hopkinson, P. Hickling, P. Lanyon, C. Laversuch, T. Lawson, R. Mallya, M. Nisar, C. Rhys-Dillon, T. Sheeran, and P.J. Maddison Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril Arthritis Rheum 56 2007 3837 3846 (Pubitemid 350100716)
15. L. Kjøller-Hansen, R. Steffensen, and P. Grande The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES) J Am Coll Cardiol 35 2000 881 888 (Pubitemid 30189917)
16. S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies, and G. Dagenais Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients The Heart Outcomes Prevention Evaluation Study Investigators N Engl J Med 342 2000 145 153
17. CardiovascularRenal Drugs Advisory Committee 90th Meeting Food and Drug Administration, Department of Health and Human Services, Center for Drug Evaluation and Research, 2000 http://www.fda.gov/ohrms/dockets/ac/00/ transcripts/3612t1b.pdf Accessed on April 22, 2011
18. A. Zanchetti, G. Crepaldi, M.G. Bond, G. Gallus, F. Veglia, G. Mancia, A. Ventura, G. Baggio, L. Sampieri, P. Rubba, G. Sperti, and A. Magni Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLISa randomized double-blind trial Stroke 35 2004 2807 2812 (Pubitemid 39565175)
19. L.H. Lindholm, H. Anderson, T. Ekbom, L. Hansson, J. Lanke, B. Dahlf, U. de Faire, K. Forsén, T. Hedner, E. Linjer, B. Scherstén, P. Wester, and T. Mller Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial Lancet 358 2001 539 544 (Pubitemid 32772729)
20. P. Tatti, M. Pahor, R.P. Byington, P. Di Mauro, R. Guarisco, G. Strollo, and F. Strollo Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM Diabetes Care 21 1998 597 603 (Pubitemid 28172941)
21. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288 2002 2981 2997
22. A.F. Lever, D.J. Hole, C.R. Gillis, I.R. McCallum, G.T. McInnes, P.L. MacKinnon, P.A. Meredith, L.S. Murray, J.L. Reid, and J.W. Robertson Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 352 1998 179 184 (Pubitemid 28327802)
23. G. Ronquist, L.A. Rodríguez, A. Ruigómez, S. Johansson, M.A. Wallander, G. Frithz, and K. Svrdsudd Association between captopril, other antihypertensive drugs and risk of prostate cancer Prostate 58 2004 50 56 (Pubitemid 38057988)
24. C.R. Meier, L.E. Derby, S.S. Jick, and H. Jick Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer Arch Intern Med 160 2000 349 353 (Pubitemid 30075217)
25. L. Perron, I. Bairati, L. Moore, and F. Meyer Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer Int J Cancer 106 2003 409 415 (Pubitemid 36870405)
26. M. Stahl, C.J. Bulpitt, A.J. Palmer, D.G. Beevers, E.C. Coles, and J. Webster Calcium channel blockers, ACE inhibitors, and the risk of cancer in hypertensive patients: a report from the Department of Health Hypertension Care Computing Project (DHCCP) J Hum Hypertens 14 2000 299 304 (Pubitemid 30311510)
27. D.M. Boudreau, E. Koehler, S.J. Rulyak, S. Haneuse, R. Harrison, and M.T. Mandelson Cardiovascular medication use and risk for colorectal cancer Cancer Epidemiol Biomarkers Prev 17 2008 3076 3080
28. S. Friis, H.T. Sørensen, L. Mellemkjaer, J.K. McLaughlin, G.L. Nielsen, W.J. Blot, and J.H. Olsen Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark Cancer 92 2001 2462 2470 (Pubitemid 33029093)
29. S. Friberg, and S. Mattson On the growth rates of human malignant tumors: implications for medical decision making J Surg Oncol 65 1997 284 297 (Pubitemid 27355857)
30. E. Braunwald, M.J. Domanski, S.E. Fowler, N.L. Geller, B.J. Gersh, J. Hsia, M.A. Pfeffer, M.M. Rice, Y.D. Rosenberg, and J.L. Rouleau Angiotensin-converting-enzyme inhibition in stable coronary artery disease N Engl J Med 351 2004 2058 2068
31. K.M. Fox Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) Lancet 362 2003 782 788 (Pubitemid 37093919)
32. S. Yusuf, K.K. Teo, J. Pogue, L. Dyal, I. Copland, H. Schumacher, G. Dagenais, P. Sleight, and C. Anderson Telmisartan, ramipril, or both in patients at high risk for vascular events N Engl J Med 358 2008 1547 1559 (Pubitemid 351522739)
33. C.I. Coleman, W.L. Baker, J. Kluger, and C.M. White Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials J Hypertens 26 2008 622 629 (Pubitemid 351354904)